Dabur Plays Steady As USFDA Flags Silvassa Unit, Says Business Unharmed

 In a market that reacts sharply to any mention of USFDA, Dabur’s message is deliberately steady. The company is framing the episode as a regulatory process to be managed, not a crisis to be contained. For now, the emphasis is on continuity of production, stable earnings visibility and cooperative engagement with the agency.  

Regulator Engagement Underway  

Dabur has confirmed it is in active dialogue with the USFDA regarding the findings at its Silvassa plant. Management has submitted a corrective action plan, signalling a willingness to swiftly address compliance gaps and align with global quality standards.  

Operations And Financials Remain Intact  

The company underlined that the Silvassa facility remains operational, with no disruption to manufacturing or supply schedules. Correspondingly, Dabur has guided that the USFDA observations have not led to any impact on its financial or operational activities at this stage.  

Key Highlights  

• Actively engaged with USFDA on inspection findings  
• Corrective action plan submitted for Silvassa unit  
• Silvassa plant remains fully operational  
• No impact on financial or operational performance indicated  

Sources: Company communication, stock exchange update